Evidence map›Paper›PMID 31252541›Full record

ArticleJournal of clinical medicine2019

Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis.

Maria L Gonzalez Suarez, Charat Thongprayoon, Michael A Mao, Napat Leeaphorn, Tarun Bathini, Wisit Cheungpasitporn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 4 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 4 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Article
  6. Article
  7. Review
  8. Review
  9. Shiga Toxin-ProducingKidney international reports · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Maria L Gonzalez SuarezDivision of Nephrology, Department of Medicine, University of Mississippi Medical Center, MS 39216, USA. malourdes.gonzalez@gmail.com.
Charat ThongprayoonDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN 55905, USA.
Michael A MaoDivision of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-1814-7003
Napat LeeaphornDepartment of Nephrology, Department of Medicine, Saint Luke's Health System, Kansas City, MO 64111, USA.
Tarun BathiniDepartment of Internal Medicine, University of Arizona, Tucson, AZ 85721, USA.
Wisit CheungpasitpornDivision of Nephrology, Department of Medicine, University of Mississippi Medical Center, MS 39216, USA.ORCID 0000-0001-9954-9711
University of Mississippi Medical Center · USMayo Clinic · USMayo Clinic in Florida · USSaint Luke's Health System · USUniversity of Arizona · US

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI HALL, JOHN E · 2016 to 2025
$38.2M
NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

backgroundKidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) is frequently complicated by recurrence, resulting in thrombotic microangiopathy in the renal allograft and graft loss. We aimed to assess the use of eculizumab in the prevention and treatment of aHUS recurrence after kidney transplantation.

methodsDatabases (MEDLINE, EMBASE and Cochrane Database) were searched through February 2019. Studies that reported outcomes of adult kidney transplant recipients with aHUS treated with eculizumab were included. Estimated incidence rates from the individual studies were extracted and combined using random-effects, generic inverse variance method of DerSimonian and Laird. Protocol for this systematic review has been registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018089438).

resultsEighteen studies (13 cohort studies and five case series) consisting of 380 adult kidney transplant patients with aHUS who received eculizumab for prevention and treatment of post-transplant aHUS recurrence were included in the analysis. Among patients who received prophylactic eculizumab, the pooled estimated incidence rates of recurrent thrombotic microangiopathy (TMA) after transplantation and allograft loss due to TMA were 6.3% (95%CI: 2.8-13.4%,

conclusionsThis study summarizes the outcomes observed with use of eculizumab for prevention and treatment of aHUS recurrence in kidney transplantation. Our results suggest a possible role for anti-C5 antibody therapy in the prevention and management of recurrent aHUS.

Indexed as

atypical hemolytic uremic syndromeeculizumabkidney transplantationmeta-analysisrenal transplantation

Identifiers

PMID31252541
PMCPMC6679118
OpenAlexW2955977081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.